Early Multifocal Electroretinogram Findings during Intravitreal Ranibizumab Treatment for Neovascular Age-Related Macular Degeneration
Investigative Ophthalmology & Visual Science2011Vol. 52(6), pp. 3446–3446
Citations Over TimeTop 25% of 2011 papers
Claudio Campa, Richard Hagan, Jayashree Sahni, Malcolm C. Brown, Nicholas A. V. Beare, Heinrich Heimann, Simon Harding
Abstract
Intravitreal ranibizumab therapy appears to induce an increase in mfERGs centrally in patients with nAMD at least in the short term. Longer term studies to investigate the prognostic value of mfERG responses to predict changes in visual acuity in nAMD and other diseases are warranted. (ClinicalTrials.gov number, NCT01023971.).
Related Papers
- → Ranibizumab for Neovascular Age-Related Macular Degeneration(2006)5,818 cited
- → Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration(2021)81 cited
- → Estimated Cases of Blindness and Visual Impairment from Neovascular Age-Related Macular Degeneration Avoided in Australia by Ranibizumab Treatment(2014)50 cited
- → Ranibizumab and aflibercept for the treatment of wet age-related macular degeneration(2015)25 cited
- → Pharmacogenetics of the Treatment Response of Age-Related Macular Degeneration with Ranibizumab and Bevacizumab(2013)13 cited